This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujise, K. Articles by Beck, P. J. Search for Related Content PubMed PubMed Citation Articles by Fujise, K. Articles by Beck, P. J.

(Circulation. 1997;95:715-722.)
© 1997 American Heart Association, Inc.

Articles

A Tissue Plasminogen Activator/P-Selectin Fusion Protein Is an Effective Thrombolytic Agent

Kenichi Fujise, MD; Bryan Mitch Revelle, BS; Lowell Stacy, PhD; Edwin L. Madison, PhD; Edward T.H. Yeh, MD; James T. Willerson, MD; Pamela J. Beck, PhD

the Divisions of Molecular Medicine and Cardiology (K.F., E.T.H.Y.), Department of Internal Medicine; Cardiovascular Research Center (K.F., E.T.H.Y.), Institute of Molecular Medicine for the Prevention of Human Diseases; and Department of Internal Medicine (K.F., E.T.H.Y., J.T.W., P.J.B.), The University of Texas Health Science Center (Houston); Texas Heart Institute (J.T.W.), Houston, Tex; Texas Biotechnology Corporation (B.M.R., L.S., P.J.B.), Houston, Tex; and Department of Vascular Biology (E.L.M.), Scripps Research Institute, La Jolla, Calif.

Correspondence to Dr Kenichi Fujise, Cardiovascular Research Center, Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas–Houston Health Science Center, Ste 4200, 6431 Fannin, Houston TX 77030. E-mail kfujise@heart.med.uth.tmc.edu.

Background P-selectin is expressed on the surface of activated endothelial cells and platelets. We hypothesized that a tissue plasminogen activator (TPA)/P-selectin fusion protein would have not only thrombolytic activity but also might target TPA to the thrombi. In addition, it seemed possible that this chimeric protein would competitively inhibit the binding of native P-selectin on endothelial cells and platelets to leukocytes and thus further promote thrombolysis.

Methods and Results The full-length, plasminogen activator inhibitor-1–resistant form of TPA (TPA_IR) together with two TPA_IR/P-selectin fusion constructs (P280_IR and P121_IR) were expressed with the use of baculovirus vectors. After infection of Sf-21 cells with the recombinant baculovirus, recombinant TPA_IR and P-selectin/TPA_IR fusion proteins were purified with the use of metal ion chromatography. The intact protease activity of TPA_IR and the ligand binding capability of P-selectin were confirmed through indirect chromogenic and cell binding assays, respectively. These molecules were assessed both in vitro and in vivo for thrombolytic activity. In vitro clot lysis assays indicated equal efficacy of TPA_IR, P280_IR, and P121_IR (P>.5). The in vivo efficacy was tested in a cyclic flow variation model with the use of the rat mesenteric artery. Compared with saline control treatment, reduction in cyclic flow variations was significant (P<.05) and similar (P>.5) among TPA_IR, P280_IR, and P121_IR. No significant bleeding was noted among treated animals.

Conclusions Chimeric proteins P280_IR and P121_IR have clot lysis activities that are similar to TPA_IR both in vitro and in vivo. These chimeric proteins also bind to P-selectin ligand in vitro. Thus, these proteins may provide an efficient method of targeting TPA to the thrombotic region. Further experimental analysis with the use of larger animal coronary occlusion models should help determine the future value of these proteins as clinical therapeutic agents.

Key Words: plasminogen activators • thrombolysis • P-selectin • cyclic flow variations • acute coronary syndromes

This article has been cited by other articles:

				B.-S. Ding, N. Hong, J.-C. Murciano, K. Ganguly, C. Gottstein, M. Christofidou-Solomidou, S. M. Albelda, A. B. Fisher, D. B. Cines, and V. R. Muzykantov Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature Blood, February 15, 2008; 111(4): 1999 - 2006. [Abstract] [Full Text] [PDF]

				K. Danielyan, B.-S. Ding, C. Gottstein, D. B. Cines, and V. R. Muzykantov Delivery of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein to the Cerebral Vasculature Lyses Arterial Clots and Attenuates Postischemic Brain Edema J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 947 - 952. [Abstract] [Full Text] [PDF]

				S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF]

				B.-S. Ding, C. Gottstein, A. Grunow, A. Kuo, K. Ganguly, S. M. Albelda, D. B. Cines, and V. R. Muzykantov Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature Blood, December 15, 2005; 106(13): 4191 - 4198. [Abstract] [Full Text] [PDF]

				A. Katoh, H. Ikeda, T. Murohara, N. Haramaki, H. Ito, and T. Imaizumi Platelet-Derived 12-Hydroxyeicosatetraenoic Acid Plays an Important Role in Mediating Canine Coronary Thrombosis by Regulating Platelet Glycoprotein IIb/IIIa Activation Circulation, December 22, 1998; 98(25): 2891 - 2898. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]